A. von Deimling

EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma

This study identifies EMP3 as a regulator of EGFR/CDK2 signaling in glioblastoma by stabilizing EGFR and promoting its oncogenic activity.

MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors

This study shows that MHC class II antigen presentation on blood-borne myeloids is essential to maintain functional CD8+ T cells in brain tumors by preventing Tox-driven dysfunction.

Reprogramming M2-polarized patient-derived glioblastoma associated microglia/macrophages via CSF1R inhibition

This study shows that GW2580 reprograms M2-like glioblastoma-associated macrophages to M1-like cells, enhancing phagocytosis and T-cell killing, and reduces tumor cell proliferation in patient-derived organoids.

Mapping pediatric brain tumors to their origins in the developing cerebellum

The paper maps the cellular origins of three common pediatric brain tumors using a single-nucleus atlas and transcriptome data, identifying lineage-specific origins and potential therapeutic targets.

A subset of pediatric thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR

This study identifies a distinct subset of pediatric gliomas with EGFR alterations, H3K27me3 loss, and broad tumor localization, suggesting EGFR inhibition as a potential therapy.

G3BP1 tethers the TSC complex to lysosomes and suppresses mTORC1 in the absence of stress granules

This paper shows G3BP1 anchors the TSC complex to lysosomes to suppress mTORC1 signaling without stress granules, and inhibits mTORC1-driven cancer and neuronal issues.

Testing of the survivin suppressant YM155 in a large panel of drug-resistant neuroblastoma cell lines

This study tests YM155 in 101 neuroblastoma cell lines, revealing ABCB1 and ABCC1 as mediators of resistance and highlighting cross-resistance differences between drug-adapted lines.